ModifiedUnitedHealthcarePolicy CS051PA.P

Gynecomastia Surgery (for Pennsylvania Only)

Medical policy governing coverage of mastectomy to treat gynecomastia for members in Pennsylvania; defines medical necessity criteria, required evaluations, and applicable billing codes.

Policy Summary

PayerUnitedHealthcare

PolicyGynecomastia Surgery (for Pennsylvania Only)

Policy CodePolicy CS051PA.P

Change TypeRevisions to wording and lab testing examples

Effective DateAugust 1, 2025

Next Review Date

Key ActionInclude CPT 19300 in prior authorization requests with supporting clinical documentation per the policy criteria.

SourceLink

POLICY UPDATE CHANGES

Replaced wording to state 'a mastectomy to treat Gynecomastia in a male is considered reconstructive and medically necessary when all of the [listed] criteria are met.'

Revised coverage criteria to change requirement from mandatory 'supporting laboratory testing must be performed' to 'supporting laboratory testing may include but is not limited to the [listed tests]'.

Updated list of supporting laboratory tests: added 'thyroid function studies, sex-hormone binding globulin' and 'alpha-fetal protein'; removed a prior duplicate mention of 'thyroid function studies'.

Removed reference link to the Medical Policy titled 'Panniculectomy and Body Contouring Procedures (for Pennsylvania Only)'.

Updated Clinical Evidence and References sections to reflect the most current information.

Grade II-IVGynecomastia stages referenced

>=2 yrsPediatric duration requirement

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage and Medical Necessity Criteria

Pediatric (under 18) - Medically Necessary

Covered when ALL of the following are met:

Pediatric mastectomy criteria: 1) Gynecomastia stage II, III, or IV with moderate to severe chest pain causing a Functional or Physical Impairment (inability to participate in athletic events, sports, or social activities alone is not considered a Functional or Physical Impairment); 2) Glandular breast tissue is the primary cause of gynecomastia (not pseudogynecomastia) documented by physical exam and/or mammography; 3) Persistent gynecomastia after cessation of prescribed medications, nutritional supplements, and appropriate screening of non-prescription and/or recreational drugs or substances known to cause gynecomastia (examples include but are not limited to testosterone, marijuana, asthma drugs, phenothiazines, anabolic steroids, cimetidine, and calcium channel blockers); 4) Gynecomastia present for at least two years; 5) Appropriate evaluation of medical causes with normal supporting laboratory testing; supporting laboratory testing may include but is not limited to hormone testing (e.g., beta-hCG, thyroid function studies, sex-hormone binding globulin, estradiol, FSH, LH, prolactin, testosterone), alpha-fetoprotein, liver enzymes, and serum creatinine.age < 18

From Coverage Rationale

Adult (18 and over) - Medically Necessary

Covered when ALL of the following are met:

Adult mastectomy criteria: 1) Gynecomastia stage II, III, or IV with moderate to severe chest pain causing a Functional or Physical Impairment (inability to participate in athletic events, sports, or social activities alone is not considered a Functional or Physical Impairment); 2) Glandular breast tissue is the primary cause of gynecomastia (not pseudogynecomastia) documented by physical exam and/or mammography; 3) Persistent gynecomastia after cessation of causative prescribed medications, nutritional supplements, and appropriate screening of non-prescription and/or recreational substances known to cause gynecomastia; 4) Appropriate evaluation of medical causes with normal supporting laboratory testing as indicated (supporting testing may include hormone testing, AFP, liver enzymes, serum creatinine); note: if tumor or neoplasm is suspected, breast ultrasound and/or mammogram may be performed with further management as indicated.

Timing expectations and conservative therapy: Specialty guideline recommendations suggest observation, addressing underlying causes, and attempting medical therapy when indicated prior to surgery; ASPS guidance notes durations for adults (e.g., persistence for >3–4 months after pathological causes are ruled out and failed medical therapy for grade III–IV) may apply as contextual guidance.

Medical Necessity — Mastectomy for Gynecomastia

Policy states mastectomy to treat gynecomastia in a male is reconstructive and medically necessary when all listed criteria are met.

Reconstructive medical necessity determination: A mastectomy to treat Gynecomastia in a male is considered reconstructive and medically necessary when all of the listed criteria are met.

See pediatric and adult criteria for the full list of required elements.

Supporting Laboratory Testing

Supporting laboratory testing for evaluation of medical causes:

Supporting lab testing: An appropriate evaluation of medical causes when supporting laboratory testing has been normal; supporting laboratory testing may include but is not limited to the following examples:

Example tests: Hormone testing (e.g., beta-human chorionic gonadotropin [beta-hCG], thyroid function studies, sex-hormone binding globulin [SHBG], estradiol, follicle-stimulating hormone [FSH], luteinizing hormone [LH], prolactin, testosterone); alpha-fetoprotein (AFP); liver enzymes; serum creatinine.

Pseudogynecomastia, defined as breast enlargement due primarily to fatty deposits rather than proliferative glandular tissue, is expressly excluded from coverage as a reconstructive mastectomy indication. Documentation must show that glandular breast tissue is the primary cause of the enlargement, demonstrated on physical exam and/or mammography, for the mastectomy to be considered reconstructive and medically necessary.

Requests may be excluded when required clinical evidence is not present. Specifically, cases lacking documentation that gynecomastia has persisted for the required duration (for pediatric members gynecomastia must be present for at least two years), lacking documentation of glandular-predominant breast tissue on exam or mammography, or lacking evidence that the condition persisted after cessation of prescribed medications, supplements, or screened recreational/non-prescription agents known to cause gynecomastia may be denied as not meeting criteria.

Informational: FDA approval alone is not a basis for coverage. Surgeries to treat gynecomastia are procedural interventions and are not regulated as FDA devices; FDA status should not be used by itself to determine coverage eligibility.

Procedures that do not meet the policy's specified clinical criteria are not covered. Examples include procedures for members who do not meet the required ASPS grade (II–IV), do not have the documented glandular predominance on exam or imaging, have not demonstrated persistence after stopping causative agents, or have not undergone expected conservative or medical therapy when indicated.

Policy history: the coverage rationale and supporting language were revised effective 08/01/2025. Revisions included clarifying phrasing about a mastectomy to treat gynecomastia in a male, changing the laboratory testing criterion language to be permissive ('supporting laboratory testing may include...'), and updating the examples of supporting laboratory tests (adding items such as alpha‑fetal protein and sex‑hormone binding globulin and adjusting the hormone test list). Clinical Evidence and References were also refreshed and the prior policy version was archived.

Procedure and Billing Codes

Covered CPT CodesCPTCovered

19300

Mastectomy for gynecomastia

Applicable Codes (policy updated)mixed

No codes listed

Duration — Pediatric gynecomastia

Required duration (pediatric)Gynecomastia must be present for at least two years.

Age groupApplies to males under age 18.

Documentation contextDuration is one of several required criteria for pediatric reconstructive mastectomy for gynecomastia.

Policy revision reference

Policy revision / effective date08/01/2025 (August 1, 2025)

Summary of changesRevised coverage rationale wording and updated supporting laboratory testing language and examples; removed a related policy link and refreshed references.

Provider Requirements, Documentation, and Prior Authorization

Prior Authorization

Prior Authorization Required

Prior authorization is required for CPT 19300 (mastectomy for gynecomastia). Providers must obtain approval before scheduling the procedure to avoid claim denials or delays.

A pre-service authorization is required for CPT 19300.
Requests should include clinical documentation supporting medical necessity per the Coverage Rationale (age/stage, glandular predominance, duration, prior conservative therapy, and relevant lab/imaging).

Prior Authorization

Prior Authorization and Use of Utilization Tools

Verify the member's benefit plan terms and applicable utilization management tools prior to submission. UnitedHealthcare may use third‑party criteria (e.g., InterQual) to assist in coverage determinations; these tools may impose additional requirements.

Check the member's federal, state, or contractual benefit terms for coverage specifics.
If applicable, confirm any InterQual or other utilization tool criteria that must be met and include resulting outputs or decision support documentation with the authorization request.

Clinical Background and Scope

Background: Gynecomastia is a benign proliferation of glandular breast tissue in males. Causes include physiologic developmental stages (neonatal, pubertal, and senescent), medication or supplement effects, systemic disease, or hormone‑producing tumors. Management ranges from observation and medical therapy to surgical mastectomy, with the choice of intervention guided by the degree of glandular tissue, symptom severity, and persistence after addressing reversible causes.

Key Definitions and Grading

Gynecomastia — definition

DefinitionGynecomastia is breast enlargement in boys or men due to a benign (non-cancerous) increase in breast tissue.

NatureBenign proliferation of glandular breast tissue; distinct from fatty enlargement (pseudogynecomastia).

SourceEndocrine Society (2022) as cited in policy definitions.

ASPS Gynecomastia scale (Grades II–IV)

Grade IIModerate breast enlargement exceeding areola boundaries with edges that are indistinct from the chest.

Grade IIIModerate breast enlargement exceeding areola boundaries with edges that are indistinct from the chest with skin redundancy present.